NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024
NPCE Stock | USD 11.53 0.39 3.50% |
About 60% of all Neuropace's shareholders are looking to take a long position. The analysis of overall sentiment of trading Neuropace stock suggests that some investors are interested at this time. The current market sentiment, together with Neuropace's historical and current headlines, can help investors time the market. In addition, many technical investors use Neuropace stock news signals to limit their universe of possible portfolio assets.
Neuropace |
MOUNTAIN VIEW, Calif., Oct. 22, 2024 -- NeuroPace, Inc. , a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The companys management will webcast a corresponding conference call beginning at 130 p.m. Pacific Time 430 p.m. Eastern Time. Investors interested in listening to the conference call ma
Read at finance.yahoo.com
Neuropace Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Neuropace can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Neuropace Fundamental Analysis
We analyze Neuropace's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neuropace using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neuropace based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Neuropace is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Neuropace Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neuropace stock to make a market-neutral strategy. Peer analysis of Neuropace could also be used in its relative valuation, which is a method of valuing Neuropace by comparing valuation metrics with similar companies.
Peers
Neuropace Related Equities
OM | Outset Medical | 9.01 | ||||
DOCS | Doximity | 4.80 | ||||
VERO | Venus Concept | 3.23 | ||||
VEEV | Veeva Systems | 2.04 | ||||
GH | Guardant Health | 1.73 | ||||
DH | Definitive Healthcare | 0.97 | ||||
CI | Cigna Corp | 0.77 | ||||
LH | Laboratory | 0.72 | ||||
MD | Mednax | 1.12 |
Complementary Tools for Neuropace Stock analysis
When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |